The clinical trials system is “broken,” according to the director of the FDA’s Center for Drug Evaluation and Research, Janet Woodcock.
The system needs new clinical trial networks and the adoption of mater protocols – protocols for trials that focus on multiple therapies for a single disease or a single treatment that could apply to multiple diseases, Woodcock said, according to RAPS.
Get the full story at our sister site, Drug Delivery Business News.
The post Clinical trials system is ‘broken’, FDA’s Woodcock says appeared first on MassDevice.
from MassDevice http://ift.tt/2wLSKw5
Cap comentari:
Publica un comentari a l'entrada